


Description

IL-33 also known as NF-HEV and DVS27 is a cytokine that belongs to the IL-1 family. It is expressed by endothelial cells, fibroblasts, bronchial and epithelial cells and some immune cells including macrophages and dendritic cells. IL-33 signaling is mediated by its receptor ST2 that exists in the soluble form (sST2) and as a transmembrane receptor (ST2L). Binding to ST2L causes activation of nuclear factor κB and MAPK pathway. sST2 is thought to act as a decoy receptor attenuating the biological activity of IL-33. IL-33 mainly promotes Th2 cytokines like IL-4, IL-5 and IL-13. It is able to activate cells of the innate and adaptive immune system. Manipulation of the IL-33/sT2 pathway is being looked at as a promising method to treat or prevent various inflammatory disorders. Elevated levels of IL-33 have been observed in chronic inflammatory diseases like asthma, rheumatoid arthritis, osteoarthritis, psoriatic arthritis, SLE, UC, and Crohn’s disease. Recent studies have suggested that IL-33 may play a role in Cardiovascular disorders. IL-33 inhibits the development of atherosclerotic plaques and induces the production of anti-oxidized LDL antibodies. It can also enhance eosinophilic perimyocarditis and impair heart function. The Simoa IL-33 assay detects both free and sST2-bound IL-33 as shown below.

Calibration Curve: Calibrator concentrations and Lower Limit of Quantification depicted.




Lower Limit of Quantification (LLOQ): Triplicate measurements of serially diluted calibrator were read back on the calibration curve over 3 runs each for 1 reagent lot across 2 instruments (6 runs total).

Limit of Detection (LOD): Calculated as 2.5 standard deviations from the mean of background signal read back on each calibration curve over 3 runs each for 1 reagent lot across 2 instruments (6 runs total).

| | |
|--|---|
| LLOQ | 0.686 pg/mL pooled CV 16% mean recovery 108% |
| LOD | 0.320 pg/mL range 0.185-0.386 pg/mL |
| Dynamic range | 0–2000 pg/mL |
| Diluted Sample volume (1:2 Dilution)* | 100 µL per measurement |
| Tests per kit | 192 |

*See Kit Instruction for details

Endogenous Sample Reading: Healthy donor matched EDTA plasma (n=10) and serum (n=10) samples were measured. Bars depict median with interquartile range. Orange line represents functional LLOQ.



| Sample Type | Mean IL-33 pg/mL | Median IL-33 pg/mL | % Above LOD |
|-------------|------------------|--------------------|-------------|
| EDTA plasma | 10.5* | 5.83* | 100% |
| Serum | 9.81* | 5.45* | 100% |

*Values below LLOQ are not included in the mean or median

Precision: Measurements of 1 endogenous serum, 2 endogenous EDTA plasma panels, and 2 calibrator-based controls. Triplicate measurements were made for 3 runs each for 1 reagent lot across 2 instruments (6 runs total, 18 measurements).

| Sample | Mean (pg/mL) | Within run CV | Between run CV | Between inst CV |
|-----------|--------------|---------------|----------------|-----------------|
| Control 1 | 28.3 | 3.1% | 8.1% | 3.9% |
| Control 2 | 409 | 3.7% | 3.7% | 4.9% |
| Panel 1 | 17.4 | 6.0% | 7.3% | 2.7% |
| Panel 2 | 5.39 | 9.5% | 5.0% | 2.3% |
| Panel 3 | 10.2 | 5.1% | 4.4% | 0.6% |

Spike and Recovery: 2 EDTA plasma and 2 serum samples were spiked at high and low concentrations within the range of the assay.

Dilution Linearity: 1 spiked EDTA plasma, 1 endogenous EDTA plasma, 1 spiked serum, and 1 endogenous serum sample were diluted serially from MRD (2x) to 16x with sample diluent.

| | |
|--|---------------------------------------|
| Spike and Recovery (Serum/Plasma) | 75% Range 65-84% |
| Plasma Dilution Linearity (16x) | Mean = 117% Range: 72-132% |
| Serum Dilution Linearity (16x) | Mean = 121% Range: 108-135% |

Specificity: Two normal serum samples and one spiked serum sample were pre-incubated with 25x IL-33 capture beads. Capture beads were removed and samples were run at MRD in the assay. Average knock-down relative to control without capture bead pre-incubation was **96%**.

Soluble IL-33 receptor (sST2) binding: 1 serum, 2 plasma, and one stimulated plasma were compared with and without the addition of 10 ng/mL IL-33 receptor sST2. No significant difference in sample reading was observed between the two conditions suggesting that the IL-33 assay recognizes both free and sST2-bound forms of the target.

| Sample | Unspiked (pg/mL) | + 10ng/mL sST2 (pg/mL) | Bias |
|---------------------|------------------|------------------------|--------|
| Serum | 1.82 | 1.73 | -5.0% |
| EDTA Plasma 1 | 2.66 | 2.47 | -7.0% |
| EDTA Plasma 2 | 0.991 | 0.993 | 0.3% |
| Stimulated plasma 1 | 1.36 | 0.966 | -28.7% |

The Simoa IL-33 Discovery assay kit is formulated for use on the SR-X®, HD-1, or HD-X® platform. Data in this document was obtained from runs on the HD-1 platform unless otherwise noted. Some differences in performance claims between SR-X and HD-1/HD-X may be observed when comparing datasheets for these platforms. This may be due to experiments run at different time-points with different reagent lots and different samples, or it may be due to minor differences in antibody and analyte behavior in the different assay formats.